# US 2025/0102524 A1 · Hemoglobin g-makassar binding polypeptides and antibodies and methods of using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0102524 A1
- Document ID: US20250102524A1
- Status: Published application
- Kind: A1
- Application number: 18/908,540
- Filed: 2024-10-07
- Published: 2025-03-27
- Earliest claimed: 2022-04-08
- Assignees: Beam Therapeutics Inc.
- Applicants: Beam Therapeutics Inc.
- Inventors: Scott Haihua Chu; Lisa Schlehuber; Manuel Ortega
- Web page: https://patentgrep.com/patent/US20250102524A1

## CPC

- C07K 16/34: against blood group antigens
- G01N 33/721: {Haemoglobin}
- C07K 14/805: Haemoglobins; Myoglobins
- C07K 16/18: against material from animals or humans
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2800/22: Haematology
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Described and featured herein are binding polypeptides and antibodies, and antigen binding portions thereof, that specifically bind to the HbG-Makassar variant polypeptide or peptide and methods of using such binding polypeptides and antibodies to specifically bind, detect, identify, select, and/or isolate the HbG-Makassar variant polypeptide or peptide, for example, in a biological sample.

## Claims

### Claim 1

A binding polypeptide, anti-HbG-Makassar antibody, or an antigen binding portion thereof that specifically binds to an hemoglobin G (HbG) Makassar variant polypeptide, or a peptide thereof, but fails to detectably bind or binds at reduced levels to a wild-type beta (β)-globin polypeptide and/or a sickle cell globin (HbS) polypeptide, or a peptide thereof.

### Claim 2 (depends on 1)

The binding polypeptide or the antibody of claim 1, comprising one or more complementarity determining regions (CDRs) which comprise or consist of heavy chain variable region (VH) CDRs and/or light chain variable region (VL) CDRs selected from the following:
A)
VH CDR1:
GIDFSRYW;
VH CDR2:
INIDSSTI;
VH CDR3:
ARAYDGYSLDY;
VL CDR1:
SSVSY;
VL CDR2:
DTS;
VL CDR3:
RQWSSYPLT;
B)
VH CDR1:
GYTFTNYF;
VH CDR2:
INPKNGGI;
VH CDR3:
ARGSANWGAY;
VL CDR1:
QRTNC;
VL CDR2:
HDL;
VL CDR3:
QQWSSYPLT;
or
C)
VH CDR1:
GYTFTSDW;
VH CDR2:
IYPRSGST;
VH CDR3:
ARGTYYGSRSYYFDY;
VL CDR1:
SSVSY;
VL CDR2:
DTS:
VL CDR3:
RQWSSYPLT,

### Claim 3 (depends on 1)

The binding polypeptide or the antibody of claim 1, which comprises or consists of:
VL CDR1
SSVSY,
VL CDR2:
DTS,
and
VL CDR3:
RQWSSYPLT
and
VH CDR1:
GIDFSRYW;
VH CDR2:
INIDSSTI;
VH CDR3:
ARAYDGYSLDY
or
VH CDR1:
GYTFTSDW;
VH CDR2:
IYPRSGST;
VH CDR3:
ARGTYYGSRSYYFDY;
VL CDR1
QRTNC;
VL CDR2:
HDL;
VL CDR3:
QQWSSYPLT
and
VH CDR1:
GYTFTNYF;
VH CDR2:
INPKNGGI;
VH CDR3:
ARGSANWGAY.
a variable heavy chain (VH) domain comprising a CDR1 comprising amino acid sequence GIDFSRYW, a CDR2 comprising amino acid sequence INIDSSTI, and a CDR3 comprising amino acid sequence ARAYDGYSLDY; or
a variable heavy chain (VH) domain comprising a CDR1 comprising amino acid sequence GYTFTSDW, a CDR2 comprising amino acid sequence IYPRSGST, and a CDR3 comprising amino acid sequence ARGTYYGSRSYYFDY; and/or
a variable light chain (VL) domain comprising a CDR1 comprising amino acid sequence SSVSY, a CDR2 comprising amino acid sequence DTS, and a CDR3 comprising amino acid sequence RQWSSYPLT.

### Claim 4 (depends on 1)

The binding polypeptide or the antibody of claim 1, comprising a heavy chain variable domain (VH) sequence having at least 85%, 90%, or 95% amino acid sequence identity to the amino acid sequence:
EVQLQESGGGLVQPGGSLKLSCAASGIDFSRYWMSWVRRAPGKGL
EWIGEINIDSSTINYAPSLKDKFIISRDNAKNTLYLQMSKVRSED
TALYYCARAYDGYSLDYWGQGTSVTVSS,
and/or comprising a light chain variable domain (VL) sequence having at least 85%, 90%, or 95% amino acid sequence identity to the amino acid sequence:
QIVLTQSPAIMSASPGEKVTMTCSTSSSVSYMFWYQQKPGSSPRL
LIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCRQW
SSYPLTFGAGTKLELK.

### Claim 5 (depends on 1)

The binding polypeptide or the antibody of claim 1, comprising a heavy chain variable domain (VH) sequence having at least 85%, 90%, or 95% amino acid sequence identity to the amino acid sequence:
EVLLQQSGPELVKPGASVKISCKASGYTFTNYFMNWVKQSHGKSL
EWIGDINPKNGGISYNQKFKGKATLIVDKSSSTAYMELRSLTSED
SAVYYCARGSANWGAYWGQGTLVTVSA,
and/or comprising a light chain variable domain (VL) sequence having at least 85%, 90%, or 95% amino acid sequence identity to the amino acid sequence:
WWEDGYSWCSISHFQLPANQCLSHTVQRTNCSRPVSSNHVCISRG
EGHHDLQCQLKFPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQW
SSYPLTFGAGTKLELK.

### Claim 6 (depends on 1)

The binding polypeptide or the antibody of claim 1, comprising a heavy chain variable domain (VH) sequence having at least 85%, 90%, or 95% amino acid sequence identity to the amino acid sequence:
QVQLQQPGAELVKPGASVKMSCKASGYTFTSDWITWVKQRPGQGL
EWIGDIYPRSGSTNYNEKFKSKATLTVDISSNTAYMQLSSLTSED
SAVFYCARGTYYGSRSYYFDYWGQGTTLTVSS,
and/or comprising a light chain variable domain (VL) sequence having at least 85%, 90%, or 95% amino acid sequence identity to the amino acid sequence:
QIVLTQSPAIMSASPGEKVTMTCSTSSSVSYMFWYQQKPGSSPRL
LIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCROW
SSYPLTFGAGTKLELK.

### Claim 7 (depends on 1)

The binding polypeptide or the antibody of claim 1, wherein the binding polypeptide or the antibody, or a binding portion thereof, comprises an affinity tag or a detectable amino acid sequence.

### Claim 8 (depends on 1)

A method of identifying an HbG-Makassar variant polypeptide or peptide, the method comprising contacting a sample with the binding polypeptide or the antibody of claim 1 for a time sufficient for the polypeptide or the antibody to bind to the HbG-Makassar variant polypeptide or peptide in the sample.

### Claim 9 (depends on 1)

An isolated nucleic acid molecule that encodes the binding polypeptide or the antibody of claim 1.

### Claim 10 (depends on 9)

The isolated nucleic acid molecule of claim 9, comprising a nucleic acid sequence having at least 85%, 90, 95, or 100% sequence identity to the heavy chain variable domain
(VH) nucleic acid sequence
gaggtgcagctgcaggagtctggaggtggcctggtgcagcctgga
ggatccctgaaactctcctgtgcagcctcaggaatcgattttagt
agatactggatgagttgggttcggcgggctccagggaaaggacta
gaatggattggagaaattaatatagatagcagtacaataaactat
gcaccatctctaaaggataaattcatcatctccagagacaacgcc
aaaaatacgctgtacctgcaaatgagcaaagtgagatctgaggac
acagccctttattactgtgcaagggcctatgatggttattcgttg
gactactggggtcaaggaacctcagtcaccgtctcctcag
and/or comprising a nucleic acid sequence having at least 85% sequence identity to the light chain variable domain (VL) nucleic acid sequence
caaattgttctcacccagtctccagcaatcatgtctgcatctcca
ggggagaaggtcaccatgacctgcagtaccagctcaagtgtaagt
tacatgttctggtaccagcagaagccaggatcctcccccagactc
ctgatttatgacacatccaacctggcttctggagtccctgttcgc
ttcagtggcagtgggtctgggacctcttactctctcacaatcagc
cgaatggaggctgaagatgctgccacttattactgccggcagtgg
agtagttaccccctcacgttcggtgctgggaccaagctggagctg
aaac;
gaggtcctgctgcaacaatctggacctgagctggtgaagcctggg
gcttcagtgaagatttcctgtaaggcttctggatacacgttcact
aactacttcatgaactgggtgaagcagagccatggaaagagcctt
gagtggattggagatattaatcctaagaatggtggtattagttac
aaccagaaatttaagggcaaggccacattgattgtagacaagtcc
tccagcacagcctacatggagctccgcagcctgacttctgaggac
tctgcagtctattattgtgcaagagggtcagctaactggggggct
tactggggccaagggactctggtcactgtctctgcag
and/or comprising a nucleic acid sequence having at least 85% sequence identity to the light chain variable domain (VL) nucleic acid sequence
tggtgggaagatggatacagttggtgcagcatcagccattttcag
cttcctgctaatcagtgcctcagtcatactgtccagaggacaaat
tgttctcgcccagtctccagcaatcatgtctgcatctccagggga
gaaggtcaccatgacctgcagtgccagctcaagttccctgttcgc
ttcagtggcagtgggtctgggacctcttactctctcacaatcagc
cgaatggaggctgaagatgctgccacttattactgccagcagtgg
agtagttaccccctcacgttcggtgctgggaccaagctggaactg
aaac;
or
caggtccagctgcagcagcctggggctgagcttgtgaagcctggg
gcttcagtgaagatgtcctgcaaggcttctggctacaccttcacc
agcgactggataacctgggtgaagcagaggcctggacaaggcctt
gagtggattggagatatttatcctcgtagtggtagtactaactac
aatgagaagttcaagagcaaggccacactgactgtagatatatcc
tccaacacagcctacatgcagctcagcagcctgacatctgaggac
tctgcggtcttttactgtgcaagagggacttactacggtagtagg
tcctactactttgactactggggccaaggcaccactctcacagtc
tcctcag
and/or comprising a nucleic acid sequence having at least 85% sequence identity to the light chain variable domain (VL) nucleic acid sequence
caaattgttctcacccagtctccagcaatcatgtctgcatctcca
ggggagaaggtcaccatgacctgcagtaccagctcaagtgtaagt
tacatgttctggtaccagcagaagccaggatcctcccccagactc
ctgatttatgacacatccaacctggcttctggagtccctgttcgc
ttcagtggcagtgggtctgggacctcttactctctcacaatcagc
cgaatggaggctgaagatgctgccacttattactgccggcagtgg
agtagttaccccctcacgttcggtgctgggaccaagctggagctg
aaac.

### Claim 11 (depends on 1)

A method of identifying and/or selecting a subject expressing an HbG-Makassar polypeptide, the method comprising:
(a) contacting a sample obtained from the subject with the binding polypeptide, the antibody, or an antigen binding portion thereof, of claim 1;
(b) detecting specific binding between the binding polypeptide, the antibody, or the antigen binding portion thereof, and an HbG-Makassar polypeptide in the sample; and
(c) identifying and/or selecting the subject as expressing an HbG-Makassar polypeptide based on the detecting step (b).

### Claim 12 (depends on 1)

A method of monitoring a subject for the production of HbG-Makassar polypeptide, the method comprising:
(a) contacting a sample obtained from the subject with the binding polypeptide, the antibody, or an antigen binding portion thereof, of claim 1 at a first time point and detecting specific binding between the binding polypeptide, the antibody, or the antigen binding portion thereof, and an HbG-Makassar polypeptide in the sample;
(b) contacting a sample obtained from the subject with the binding polypeptide, the antibody, or the antigen binding portion thereof, of claim 1 at one or more additional time points and detecting specific binding between the binding polypeptide or the antibody and an HbG-Makassar polypeptide in the sample; and
(c) monitoring that the subject is expressing the HbG-Makassar polypeptide by detecting the same level or a greater level of the HbG-Makassar polypeptide in the subject's sample in step (b) versus step (a).

### Claim 13 (depends on 1)

A method of assessing a relative or absolute level of HbG-Makassar hemoglobin in a subject expressing an HbG-Makassar polypeptide, the method comprising:
(a) contacting a sample obtained from the subject with the binding polypeptide, the antibody, or an antigen binding portion thereof, of claim 1;
(b) detecting specific binding between the binding polypeptide, the antibody, or the antigen binding portion thereof, and an HbG-Makassar polypeptide in the sample; and
(c) assessing a relative or absolute level of at least 30% of HbG-Makassar hemoglobin in the sample based on the detecting step (b); wherein said level of HbG-Makassar in the subject is sufficient to prevent sickling by HbG-S hemoglobin in the subject.

### Claim 14 (depends on 13)

The method of claim 13, wherein the anti-HbG-Makassar antibody comprises 1C10.E3.G7, 1C10.C1.C7, or 5D6.F6.D2, or an antigen binding portion thereof.

### Claim 15 (depends on 1)

A composition comprising the binding polypeptide or the antibody of claim 1, or an antigen binding fragment thereof, or the nucleic acid encoding the binding polypeptide or the antibody.

### Claim 16 (depends on 1)

A vector comprising a nucleic acid molecule that encodes the binding polypeptide or the antibody of claim 1.

### Claim 17 (depends on 15)

A cell comprising the vector of claim 15.

### Claim 18 (depends on 1)

A kit comprising the binding polypeptide, the antibody, or an antigen binding portion thereof, of claim 1 or the nucleic acid molecule encoding the binding polypeptide or the antibody.

### Claim 19 (depends on 1)

The binding polypeptide, the anti-HbG-Makassar antibody, or an antigen binding portion thereof, of claim 1, wherein the polypeptide, antibody, or the antigen binding portion thereof specifically binds to a hemoglobin G (HbG) Makassar peptide comprising the amino acid sequence VHLTPAEKSAVTA.

### Claim 20 (depends on 18)

The binding polypeptide, the anti-HbG-Makassar antibody, or an antigen binding portion thereof, of claim 18, wherein the polypeptide, antibody, or the antigen binding portion thereof specifically binds to a hemoglobin G (HbG) Makassar peptide comprising the amino acid sequence VHLTPAEKSAVTA, but fails to detectably bind or binds at reduced levels to a sickle cell HbS peptide comprising the amino acid sequence VHLTPVEKSAVTA and/or to a wildtype beta-globin peptide comprising the amino acid sequence VHLTPEEKSAVTA.
